Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Sorafenib in Recurrent High-Grade Gliomas
NCT01434602Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2012
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus and sorafenib in glioblastoma (GBM) and anaplastic glioma, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose of Everolimus at 28 days. Started Oct 2012; status: completed.
02
Drugs
everolimussorafenib
03
Conditions
glioblastoma (GBM)anaplastic glioma
Beyond the preview
Go deeper on NCT01434602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01434602.